U.S. MARKETS FOR TISSUE-ENGINEERED SKIN REPLACEMENTS/SUBSTITUTES AND ACTIVE WOUND REPAIR MODULATORS
Search Inside This Report:
In 2004, the United States (U.S.) market for tissue-engineered skin replacements/substitutes and active wound repair modulators, was valued at approximately $195 million. During the forecast period covered by this report, sales are expected to increase at a compound annual rate of 9.5%, reaching approximately $481 million in the year 2014.
This report from Medtech Insight includes analyses of products, competitors, current and forecast markets, opportunities in the U.S. skin replacements/substitutes and active wound repair modulators market, as well as technologies. Topics discussed in this report include allografts, autografts, extrinsic and intrinsic factors affecting wound closure, gene therapy agents, growth factors, major wound types, the physiology of wound closure, and xenografts.
i. Tissue-Engineered Skin Replacements/Substitutes
ii. Active Wound Repair Modulators
Exhibit ES-1: 2005, Skin Replacement Product Types
Exhibit ES-2: Tissue-Engineered Skin Replacements/Substitutes, Market Forecast, 2004-2014
Exhibit ES-3: Growth Factors, Market Forecast, 2004-2014
1. CLINICAL ISSUES IN WOUND MANAGEMENT
1.1 Physiology of Wound Closure
1.1.1 Layers of the Skin and Supporting Structures
22.214.171.124 Subcutaneous Tissue
1.1.2 Wound Closure Process
126.96.36.199 Remodeling Phase
1.2 Factors Affecting Wound Closure
1.2.1 Extrinsic Factors
188.8.131.52 Medications and Other Treatment Modalities
184.108.40.206 Necrotic Tissue and Debris
220.127.116.11 Wound Creation and Depth
18.104.22.168 Wound Closure Techniques
22.214.171.124 Other Extrinsic Factors
1.2.2 Intrinsic Factors
126.96.36.199 Body Build
188.8.131.52 Chronic Illness and Age
1.2.3 Complications of Wound Healing
1.3 Major Wound Types
1.3.2 Arterial Ulcers
1.3.4 Diabetic Ulcers
1.3.5 Pressure Ulcers
1.3.6 Surgical Wounds
1.3.7 Traumatic Wounds
1.3.8 Venous Ulcers
1.4 Incidence of Major Wound Types
Exhibit 1-1: The Skin's Layers and Supporting Structures
Exhibit 1-2: Phases of the Wound Closure Process
Exhibit 1-3: Intrinsic and Extrinsic Factors Affecting Wound Closure
Exhibit 1-4: Major Wound Types, by Cause
Exhibit 1-5: Stages of Burn Wounds
Exhibit 1-6: Stages of Pressure Ulcers
Exhibit 1-7: 2002, Inpatient and Outpatient Surgery, Procedure Volumes
Exhibit 1-8: 2004, Incidence of Major Wound Types
2. TISSUE-ENGINEERED SKIN REPLACEMENTS/SUBSTITUTES
2.4 Autologous and Tissue-Engineered Skin Replacements/Substitutes
2.4.1 Epidermal Equivalent Products
2.4.2 Dermal Equivalent Products
2.4.3 Multilayer Equivalent Products
2.5 Market Forecast
2.6 Competitive Analysis
Exhibit 2-1: 2005, Skin Replacement Product Types
Exhibit 2-2: 2005, Selected Current and Emerging Tissue-Engineered Skin Replacements/Substitutes
Exhibit 2-3: Tissue-Engineered Skin Replacements/Substitutes, Market Forecast, 2004-2014
Exhibit 2-4: 2004, Tissue-Engineered Skin Replacements/Substitutes Market, Share by Supplier
3. ACTIVE WOUND REPAIR MODULATORS
3.1 Growth Factors
3.1.1 Growth Factor Classification
184.108.40.206 Fibroblast Growth Factor
220.127.116.11 Transforming Growth Factor
18.104.22.168 Epidermal Growth Factor
22.214.171.124 Platelet-Derived Growth Factor
126.96.36.199 Insulin-Like Growth Factor
188.8.131.52 Keratinocyte Growth Factor
184.108.40.206 Vascular Endothelial Growth Factor
220.127.116.11 Autologous Growth Factor
18.104.22.168.3 Harvest Technologies
22.214.171.124.5 PlasmaSeal/Hanuman Medical
126.96.36.199 Summary of Angiogenic Growth Factors
3.1.2 Competitors and Products
3.1.3 Market Forecast
3.2 Gene Therapy Agents
3.3 Other Active Wound Repair Modulators and Pharmaceuticals
3.3.1 Antibiotics and Anti-Infectives
3.3.3 Matrix Metalloproteinase Enzyme Inhibitors
3.3.4 Neuropeptides in Diabetic Wounds
3.3.5 Stem Cells
3.3.6 Other Products
Exhibit 3-1: Selected Growth Factors in Development for Wound Healing Applications
Exhibit 3-2: 2005, Selected Angiogenic Growth Factors
Exhibit 3-3: Growth Factors, Market Forecast, 2004-2014
Exhibit 3-4: Preclinical Gene Therapy Studies, 1998-2004
4. COMPANY PROFILES
4.1 Biomet, Inc.
4.2 Ethicon, Inc./Johnson & Johnson
4.3 Genentech, Inc.
4.4 Genzyme Biosurgery, Inc./Genzyme Corporation
4.5 Healthpoint Ltd./DFB Pharmaceuticals, Inc.
4.6 Integra LifeSciences, Inc./Integra LifeSciences Holdings Corporation
4.7 LifeCell Corporation
4.8 Organogenesis, Inc.
4.9 Ortec International, Inc.
4.10 RegeneRx Biopharmaceuticals, Inc.
4.11 Smith & Nephew plc
4.12 TEI Biosciences Inc.
- Biomet, Inc.
- Ethicon, Inc./Johnson & Johnson
- Genentech, Inc.
- Genzyme Biosurgery, Inc./Genzyme Corporation
- Healthpoint Ltd./DFB Pharmaceuticals, Inc
- Integra LifeSciences, Inc./Integra LifeSciences Holdings Corporation
- LifeCell Corporation
- Organogenesis, Inc.
- Ortec International, Inc.
- RegeneRx Biopharmaceuticals, Inc.
- Smith & Nephew plc
- TEI Biosciences Inc.